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Abstract
Cholecystokinin (CCK) facilitates the process of satiation via activation of vagal afferent neurons innervating the upper
gastrointestinal tract. Recent findings indicate CCK acts on these neurons via a ruthenium red (RuR) sensitive pathway that
involves members of the vanilloid (V) subfamily of transient receptor potential (TRP) channels. To further test this
mechanism, the mouse provides an ideal model in which genetic tools could be applied. However, whether CCK acts by
similar mechanism(s) in mice has not been determined. In the present study we explored the actions of CCK on nodose
neurons isolated from Sprague Dawley (SD) rat and two strains of mice; C57BL/6 and BalbC using fluorescence-based
calcium imaging. With minor exceptions nodose neurons isolated from all species/strains behaved similarly. They all
respond to brief depolarization with a large calcium transient. A significant subset of neurons responded to capsaicin (CAP),
a TRPV1 agonist, although neurons from C57BL/6 were 10-fold more sensitive to CAP than SD rats or BalbC mice, and a
significantly smaller fraction of neurons from BalbC mice responded to CAP. CCK-8 dose-dependently activated a
subpopulation of neurons with similar dose dependency, percent responders, and overlap between CCK and CAP
responsiveness. In all species/strains CCK-8 induced activation was significantly attenuated (but not completely blocked) by
pretreatment with the TRPV channel blocker RuR. Surprisingly, the CCK analogue JMV-180, which is reported to have pure
antagonistic properties in rat but mixed agonist/antagonist properties in mice, behaved as a pure antagonist to CCK in both
rat and mouse neurons. The pure antagonistic action of JMV-180 in this in vitro preparation suggests that prior reported
differential effects of JMV-180 on satiation in rats versus mouse must be mediated by a site other than vagal afferent
activation.
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Introduction
Coordination of behavioral and physiological responses follow-
ing ingestion of food is critically dependent on neuronal
transmission from the gastrointestinal (GI) tract to the brain [1].
The predominant sensory innervation of upper GI structures;
including the stomach, duodenum, and portal vasculature, is
provided by visceral afferents contained in the vagus nerve [2].
Release of the peptide cholecystokinin (CCK) from duodenal
epithelium upon the arrival of nutrients into the duodenum
activates vagal afferent terminals via CCK-1 receptors; a critical
step in slowing gastric emptying, increasing pancreatic secretion,
and facilitating the process of satiation [3]. GI projecting afferents
provide key pre-absorptive nutritional information to the brain [4]
and show enriched responsiveness to CCK [5]. In vagal afferents
CCK acts via the low-affinity binding site [6–9] to decrease K
+
[10,11] and increase non-selective cationic conductances [11],
resulting in membrane depolarization and action-potential
generation [9,12]. However, the specific cellular transduction
pathway(s) and ionic conductances targeted by CCK binding at
CCK-1 receptors remain incompletely characterized [13].
Over the last 25 years pancreatic acinar cells and heterologous
expression systems have been used to detail the signal transduction
mechanisms of the CCK-1 receptor [14,15]. As a result we now
appreciate that CCK receptor signaling is complex; with coupling
to multiple G-proteins (although coupling to Gq is the best
characterized) and activation of numerous transduction pathways
(including phospholipase C (PLC), phospholipase A2 (PLA2),
adenylyl cyclase, mitogen activated protein (MAP) kinase cascades,
and the phosphoinositol-3-kinase (PI3K) pathway) [14,15]. The
receptor also exists in different affinity states, with each state
coupling to distinct pathways and mediating specific actions [15].
While investigators have consistently found that in the rat the
actions of CCK on vagal afferents are mediated by the low-affinity
site [8,16,17], the signal pathway downstream of this activation
remains elusive. For example, Heldsinger et al. (2011) reported
that protein kinase C (PKC) mediates CCK-1 receptor actions via
PI3K and MAP-kinase pathways; while Zhao et al. (2011) reported
that inhibitors of PKC, PI3K, and PLA2 do not block CCK
actions. The basis for these conflicting results remains unknown.
Clearly multiple conductances are involved in the activation of
vagal afferents [10,11,13], and the intracellular pathways appear
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34755complex. Zhao et al. (2011) conclude that activation is likely due to
a change in phosphoinositol 4,5-bisphosphate content of the
membrane which directly leads to activation of TRP conductanc-
e(s), likely to be TRPV3 and/or V4 [13].
To further test the mechanisms of CCK-induced activation of
vagal afferents, the mouse would be an ideal model in which
genetic tools could be applied. However, the extent to which CCK
activation of vagal afferents from the mouse are similar to
responses observed in the rat has not been determined. Multiple
TRP channels (including TRPV1-4, TRPC1/3/5/6, TRPM8,
and TRPA1) are clearly expressed in rat vagal afferents [18];
however, in select species of mouse one putative CCK mediator,
TRPV3, was not detected in vagal afferents innervating the upper
GI [19]. Further, the CCK-1 receptor in mouse reacts differently
to the CCK analogue JMV-180. At the high affinity CCK site on
the CCK-1 receptor JMV-180 behaves as a full agonist in both
rats and mice, however at the low affinity site JMV-180 is a partial
agonist with extremely low efficacy in the rat, often making it a
functional antagonist, whereas in the mouse its efficacy is higher
such that it behaves more like the full agonist CCK [20]. Because
it is not fully clear how these two affinity sites couple to activation
in nodose neurons and that the downstream pathways connected
to CCK receptor activation in nodose neurons may be different
from those characterized in acinar cells, whether CCK acts
differently on mouse vagal afferents compared to the rat is an open
question.
In the present study we used measurements of cytosolic calcium
via fluorescent imaging to compare mechanisms of CCK
activation in cultured vagal afferent neurons from Sprague-
Dawley (SD) rats with two strains of mice (C57BL/6 and BalbC).
Specifically, the C57BL/6 strain is commonly used as the
background for spontaneous and targeted mutations [21]; while
BalbC mice are used extensively to study vagally mediated
neuroimmune responses in the GI tract [22]. The use of
fluorescent calcium imaging enable us to directly assess the actions
of added compounds on the target cells without the complication
of potential indirect actions that may occur in a less reduced
preparation. We found that with minor exceptions, nodose neuron
from all species/strains behaved similarly. Unexpectedly, this
included a pure antagonistic action of JMV-180 in both rats and
mice. These findings suggest that the mechanisms of CCK
induced activation of vagal afferent neurons is conserved across
species, and that mouse primary vagal afferent cultures may
provide a useful tool in the dissection of CCK-1 receptor signal
transduction pathways. However, the existing explanation for
differential behavioral effects of JMV-180 on satiation in mice
versus rat, in which a mixed agonist/antagonist action versus pure
antagonist action (respectively) was used to explain the differences
[17], needs to be reconsidered.
Materials and Methods
Animals
Nodose ganglia were isolated from adult male SD rats (240–
400 g; Simonsen Laboratories), Balb/C mice (20–30 g; Harlan),
and C57BL/6 mice (20–30 g; Harlan) by procedures approved by
the Institutional Animal Care and Use Committee (IACUC) at
Washington State University.
Cell Isolation and Primary Culture
For all species/strains animals were always sacrificed at a similar
time in the circadian cycle (,3 hours after lights on) and
measurements commenced at a similar time the following day.
Nodose ganglia were isolated from animals under a deep plane of
anesthesia (Ketamine, 25 mg/100 g; with Xylazine, 2.5 mg/
100 g) using aseptic surgical conditions. Following a midline
incision in the neck, the musculature of the next was retracted and
blunt dissection techniques were used to dissociate the common
vagal trunk from the carotid artery. In mice, high-magnification
optics (10–100x dissecting scope; Leica Microsystems, Buffalo
Grove, IL) were necessary to visualize the nodose ganglia. Once
isolated, nodose ganglia were digested in Ca
2+/Mg
2+ free Hank’s
Balanced Salt Solution containing 1 mg/mL of both Dispase II
and Collagenase Type 1A (120 min at 37uC in 95% air/5% CO2).
Neurons were dispersed by gentle trituration through silicanized
pipettes, and then washed in Dulbecco’s Modified Eagle’s Medium
(DMEM) supplemented with 10% fetal bovine serum (FBS) and
1% penicillin-streptomycin. Dispersed cells were plated onto poly-
lysine coated coverslips and maintained in DMEM+10% FBS
(37uC in 95% air/5% CO2). Measurements were made within
24 hours of isolation.
Calcium Measurements
Calcium measurements were made with the fluorescent Ca
2+
indicator Fura-2. Experiments were performed at room temper-
ature (21uC) in a physiological saline bath (in mM: 140 NaCl;
5 KCl; 2 CaCl2; 1 MgCl2; 6 glucose; 10 HEPES with pH
adjusted to 7.4 with NaOH). High K
+ bath (HiK) had 55 mM
KCl with an equimolar reduction of NaCl to 90 mM. Neurons on
coverslips were loaded with 1 mM Fura-2-AM for one hour at
room temperature followed by a 15 minute wash for de-
esterification. Coverslips were mounted into an open chamber
and constantly perfused with physiological bath. Neurons
containing Fura-2 were alternately excited with 340 and 380 nm
light with fluorescence monitored at 510 nm. Data points were
collected at 6 second time points. Ratios of fluorescence intensity
were converted to calcium concentrations using a standard curve.
Data collection was controlled with MetaFluor software.
Drugs
Drugs used are as follows (abbreviation, stock concentration,
stock solvent, and supplier): cholecystokinin-octapeptide (CCK,
100 mM, H2O, Peptides International); Capsaicin (Cap, 10 mM,
100% EtOH, Sigma-Aldrich); Ruthenium Red (RuR, 10 mM,
H2O, Tocris), BOC- Tyr(SO3H)-Nle-Gly-Trp-Nle-Asp-2-pheny-
lethylester NH3 (JMV-180, 1 mM, DMSO, Research Plus Inc.).
Statistics
For each experiment, data were collected from 2–3 nodose
ganglion cell cultures from each specie/strain. Generally, protocols
were designed to be within subject and analyzed using repeated
measures ANOVA followed by post-hoc comparisons against
control. Parameters of dose-response relationships (EC50, slope,
maximum) were determined by sigmoid fit of the data. For
antagonist studies (ruthenium red, JMV-180) all neurons received
each treatment and were compared using within subject t-tests.
Experiments detailing the proportion of responsive neurons (CAP,
CCK, CCK/CAP overlap) report the percent responders
averaged across multiple experimental days. Data are expressed
as the average 6 SEM. Statistical analysis was performed using
SigmaStat software (Systat Software Inc., San Jose, CA).
Results
While isolated mouse nodose neurons have been previously used
for electrophysiological studies [23], reports demonstrating
calcium measurements in this preparation have not been made.
Thus we first needed to establish the similarities/differences in
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Neurons from SD rats versus either strain of mouse had no obvious
morphological differences (Figure 1A). Cultures could be main-
tained for over 3 days; however, experiments reported in this
communication were performed approximately 24 hrs after
isolation. Like the SD rat, cultured vagal afferents from BalbC
and C57BL/6 mice were capable of maintaining low basal calcium
levels for extended periods of time and exhibited rapid, robust, and
reversible responses when challenged with high K
+ (55 mM)
containing baths, indicating viable expression of voltage-activated
calcium channels and normal calcium sequestration pathways
(Figure 1B). A small, but statistically significant, difference in basal
calcium concentrations was detected across populations of neurons
from the SD rat, BalbC, and C57BL/6 mice (Figure 1B and C). In
addition, a small, but statistically lower calcium response to
depolarization was seen in the rat compared to mice (Figure 1C).
Primary vagal afferent neurons are broadly classified as A-, Ad-,
or C-fibers based on the extent of myelination and resulting axonal
conduction velocities [24]; with extensively myelinated A-fibers
able to conduct action-potentials ten to twenty-fold faster than
unmyelinated C-fibers. The TRPV1 ion channel is preferentially
expressed in C- and Ad-fibers and not in A-fibers; providing a
pharmacological marker of fiber subtype in cultured neurons
where myelination is not maintained [25]. The TRPV1 agonist,
CAP, dose-dependently activated a subpopulation of vagal
afferents identifying them as TRPV1-expressing C- and Ad-fibers
(Figure 2A). Across TRPV1+ afferents, increasing concentrations
of CAP increased both the peak magnitude and duration of the
calcium transient (Figure 2B). The threshold to maximal response
in all species/strains occurred over an approximately ten-fold
concentration range (Figure 2C). The magnitude of the calcium
response was not significantly different between species/strains
(Figure 2C); however, the EC50 for CAP was lower in afferents
taken from C57BL/6 mice (Figure 2C). The proportion of CAP
sensitive afferents from the SD rat was 80 6 6%; somewhat higher
than previously reported values [26]. Both strains of mice had
lower percentages of CAP responsive afferents; with the percent
responsive in BalbC, but not the C57BL/6, reaching statistical
significance (Figure 2D).
In the rat, CCK activates a subpopulation of vagal afferent
neurons via binding at the CCK-1 receptor subtype [6–8]. CCK
produces a rapid calcium transient that requires the influx of
extracellular calcium [7,8] independent of voltage-gated calcium
channels [13] and that begins to fall even with the continued
presence of CCK. As in the rat, CCK increased cytosolic calcium
concentrations in a subgroup of neurons from both the C57BL/6
and BalbC mice (Figure 3). CCK-induced activation was dose-
dependent with maximal activation occurring by 10 nM CCK
(Figure 3A and 3B). Across species/strains the dose-response
relationships were nearly identical (Figure 3B). In this sample,
CCK activated approximately 40% of all nodose neurons across
species/strains (Figure 3C); consistent with previous findings in the
rat [8]. A majority of CCK responsive neurons were also sensitive
to CAP (Figure 3D); suggesting preferential activation of C- and
Ad-fibers by CCK [12]. There were no significant differences in
the magnitude and dose response characteristics of CCK induced
activation between CAP-sensitive and CAP-insensitive afferents
(data not shown). Because of this the responses to CCK from both
CAP-sensitive and CAP-insensitive neurons were combined for the
Figure 1. Primary cultures of nodose ganglion neurons from either rat (SD) or mouse (BalbC and C57BL/6) are viable and maintain
similar intracellular calcium homeostasis. A) Brightfield photomicrographs of cultured vagal afferent neurons taken from SD rat (left), BalbC
mouse (middle), and C57BL/6 mouse (right). Viable neurons maintained a distinct cellular membrane and had smooth, rounded profiles. Measurement
bar on right hand photomicrograph is applicable to all images. B) Representative traces of intracellular calcium concentrations from individual
neurons. Brief depolarization with elevated K
+ (HiK) produced transient increases in cytosolic calcium that decayed to baseline over time; consistent
with normal calcium buffering and sequestration. C) Across species there was small, but statistically significant difference between basal calcium
concentrations (ANOVA, P , 0.05) and Hi-K
+ evoked transient responses (ANOVA, P , 0.01). (SD rat, n = 132; BalbC mouse, n = 162; and C57BL/6
mouse, n = 121 neurons).
doi:10.1371/journal.pone.0034755.g001
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In rat CCK activates vagal afferent neurons in large part by
increasing a RuR-sensitive conductance; likely a TRPV channel
subtype [13]. We confirmed this action in rat (Figure 4C, left hand
panel). Further, we found that RuR had similar actions in neurons
from both strains of mice (Figure 4). By itself (10 mMo r3 0mM),
RuR produced no change in the basal calcium concentration, but
significantly attenuated the CCK-induced calcium transient
(Figure 4A and B, top panels). In control experiments, repeated
exposure to CCK did not produce a significant desensitization
(Figure 4A and B, bottom panels). In all species/strains reduction
in the calcium transient induced by CCK by 10 mM and 30 mM
RuR were similar in magnitude although recovery tended to be
more complete after treatment with 10 mM. These findings
demonstrate that the linkage between CCK receptor activation
and calcium influx through a RuR-sensitive conductance(s) in
nodose neurons is preserved between rat and mice. However,
given the inability of RuR to completely block the response,
additional RuR-insensitive pathways are likely to also be involved.
CCK-1 receptors have both high (pM) and low (nM) affinity
ligand binding sites that mediate distinct signaling cascades and
physiologic processes [27]. The CCK analogue, JMV-180, is a full
agonist at the high affinity site, but is a partial agonist at the low
affinity site [28] with different degrees of efficacy in the rat versus
the mouse [29,30]. Thus if the specific response under study is
mediated by the low affinity site, JMV-180 can have primarily
agonistic actions (often observed in the mouse), or in the presence
of CCK, to have antagonistic actions, especially in the rat [28–30].
In rat nodose neurons we found that JMV-180 by itself had no
effect to induce a calcium signal (100 pM – 100 nM, data not
shown), and that it produced a near complete block of the actions
of CCK in a reversible manner (Figure 5), thus confirming the low
affinity site as the relevant site for CCK actions in this preparation
and that the weak partial agonism reported for JMV-180 at this
site is inadequate to induce a calcium response in nodose neurons.
Unexpectedly, we found that JMV-180 behaved identically in both
strains of mice as it did in the rat. It had no actions by itself
(100 pM to 100 nM, data not shown), and it produced a near
complete block of the actions of CCK in a reversible manner
(Figure 5).
Discussion
The primary finding of this study is the conserved distribution
and cellular mechanism of CCK activation at vagal afferent
neurons across rat and mouse species. In the rat, CCK activates
vagal afferents through the CCK-1 receptor isoform at low
nanomolar concentrations, consistent with binding at the low
affinity site [8,16,17]. This concentration-response relationship is
maintained in mouse cultured vagal afferents, with activation
resulting in a monophasic rise in cytosolic calcium which begins to
desensitize in the continued presence of CCK. The overall
percentage of CCK responsive neurons, and their distribution
across afferent phenotype (A- vs. C- & Ad-fibers), as functionally
defined with CAP, were not different between species/strains.
Figure 2. Comparison of responses to CAP in nodose ganglion neurons from SD rat, BalbC mouse, and C57BL/6 mouse.A ) CAP induces
dose dependent increases in cytosolic calcium concentrations in a subpopulation of vagal afferents (black). Some neurons are resistant to CAP even
at the highest concentrations tested, but increase calcium following depolarization indicating normal cell viability (gray). Traces are from
representative neurons taken from a SD rat. B) High concentrations of CAP increased both the peak and integrated calcium responses. Traces are
averages 6 SEM across responsive neurons from SD rat (n = 22). C) CAP dose response relationships across species: C57BL/6 mouse,n=8 ,E C 50 =1 0
6 2 nM CAP, slope = 2.09 6 0.53, max = 371 6 89 nM calcium; BalbC mouse,n=4 ,E C 50 =5 46 26 nM CAP, slope = 1.59 6 0.70 max = 283 6
179 nM calcium; and SD rat, n = 22, EC50 =4 26 6 nM CAP, slope = 2.21 6 0.29, max = 225 6 15 nM calcium. Peak calcium influx was not
significantly different between groups (ANOVA, P = 0.84); however, the EC50 was lower in neurons from C57BL/6 mice compared to both SD rat and
BalbC mice due to larger calcium responses at the 10 nM (P , 0.001) and 30 nM (P , 0.001) CAP concentrations. D) Percent of neurons responsive to
CAP (100 nM) relative to all HiK responsive neurons within an isolation (SD rat,8 06 6%, combined n = 51/63; BalbC,4 66 10%, combined n = 38/
82; C57BL/6,6 46 1%, combined n = 27/42). Both strains of mice had lower percentages of CAP responsive afferents; with the BalbC (Holm-Sidak
post-hoc test, P = 0.009), but not the C57BL/6 (Holm-Sidak post-hoc test, P = 0.40) afferents statistically lower compared to those taken from the SD
rat.
doi:10.1371/journal.pone.0034755.g002
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equally attenuated by RuR. Unexpectedly, JMV-180 had pure
antagonistic actions in the mouse when prior studies on pancreatic
acinar cells would have suggested we should have observed some
agonistic actions in this preparation [20,29,31–33]. These
observations demonstrate that while vagal afferents isolated from
the mouse may be a useful tool for further dissecting CCK actions
on nodose neurons, one cannot assume that the relationship
between activation at a particular affinity state/site and activation
of subsequent downstream pathways as characterized in the acinar
cells will simply transfer to the downstream pathways activated by
CCK-1 receptors in nodose neurons.
CAP Identification of Vagal Afferent Phenotypes
Reductions in food intake by CCK are initiated via activation of
CAP sensitive subdiaphragmatic vagal afferents [34]. CAP is a
selective agonist at the TRPV1 ion channel and serves to
operationally define unmyelinated (C-fiber) and lightly myelinated
(Ad-fiber) afferents in the absence of conduction velocity
measurements [25]. In all species/strains tested, increasing
concentrations of CAP increase both the peak and duration of
the cytosolic calcium transient in a similar manner; identifying
subpopulations as expressing TRPV1. We found the dose-response
relationship for CAP to be very steep (Hill coefficients ,2). This
steep dose-response relationship is similar to prior reports for both
rat [35,36] and mouse [37]. Interestingly, the dose-response curve
was shifted significantly to the left in afferents from C57BL/6 mice
compared to either the SD rat or BalbC mouse. That there is a
difference between mouse strains, when the primary structure of
TRPV1 is similar, suggests a contextual co-factor present in one
but not the other strain may influence sensitivity to CAP. A second
difference noted was that the percentage of CAP responsive vagal
afferents was significantly lower in the BalbC mouse versus the SD
rat, with the C57BL/6 mouse having an intermediate number. It
remains unknown whether this finding corresponds to a
differential distribution of myelinated versus unmyelinated fibers
in vivo, and if there are functional consequences to having lower
percentages of TRPV1-expressing vagal afferents. Such a
difference would predict lower TRPV1-mediated glutamate
release at the central terminals of vagal afferents in the Balb/C
mouse [38,39], which may impact the relay of satiation signals via
the vagus.
Conserved CCK Activation of Vagal Afferents Across
Species
CCK directly activates a subpopulation of vagal afferent
neurons through binding at the CCK-1 receptor [6–8]. In the
rat CCK consistently activates ,40% of the neurons obtained
from measurements in which the innervation targets of nodose
neurons are unidentified [8,40]. We have previously found that
when retrogradely transported dyes are used to identify the
stomach or duodenum as the innervation target, ,70% of the
nodose neurons respond to CCK [5]. Given that ,70% of the
afferent vagal fibers innervate GI structures [41], one can calculate
that if a neuron responds to CCK, it is highly likely to be a neuron
that innervates a GI structure (70% of 70% equals ,50% of all
fibers). This is actually a slight overestimate of how many
unidentified nodose neurons should respond to CCK, which
could be explained by the assumption that even within GI
innervating vagal afferent fibers, there is a selective responsiveness
to CCK in neurons that innervate only the stomach and/or
duodenum. Since we did not verified that a similar enrichment of
Figure 3. Cholecystokinin (CCK) produces nearly identical activation of cultured vagal afferents from the rat and mouse species. A)
CCK produces dose dependent increases in cytosolic calcium concentrations in a subpopulation of vagal afferents. Neurons were also challenged
with CAP to determine afferent subtype and HiK to verify viability (data not shown). Trace is from a representative neuron taken from a C57BL/6
mouse. B) CCK dose response relationships across species/strains: C57BL/6 mouse,n=4 ,E C 50 = 0.60 6 0.22 nM CCK, slope = 1.24 6 0.26, max =
108 6 23 nM calcium; BalbC mouse,n=5 ,E C 50 = 0.92 6 0.77 nM CCK, slope = 3.03 6 29.5, max = 99 6 31 nM calcium; and SD rat,n=7 ,E C 50 =
0.95 6 0.35 nM CCK, slope = 1.58 6 0.40, max = 77 6 10 nM calcium. C) Percent of total viable neurons tested responsive to CCK. Results from
challenges with 10 nM CCK were used to determine population characteristics (SD rat,4 56 5%, combined n = 35/75; BalbC,3 36 6%, combined n
= 41/111; C57BL/6,4 06 2%, combined n = 38/90). D) Percent of CCK responsive neurons also activated by CAP (SD rat,6 76 9%, combined n = 15/
21; BalbC,9 06 6%, combined n = 17/19; C57BL/6,6 96 3%, combined n = 13/19).
doi:10.1371/journal.pone.0034755.g003
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mouse, we do not know for certain that a similar restriction on the
innervation targets for CCK responsive neurons is also present,
but given the similarities in other factors (percentage responsive to
CCK and CAP, and overlap between CCK and CAP responsive
neurons), one is led to a similar conclusion that responsiveness to
CCK by a nodose neuron from a mouse indicates a high likelihood
that the neuron innervated a GI structure. The findings that the
CCK and CAP response patterns are so similar in mouse and rat is
consistent with in vivo studies investigating CCK induced reduction
of food intake in mice [42], and suggest conserved mechanisms of
CCK activation of vagal afferents between rats and mice.
Identifying the Membrane Conductance(s) Activated by
CCK
CCK acting at vagal afferent neurons produces a net
depolarizing current resulting in increased membrane excitability
[11,12]. This activation occurs independently of voltage-activated
calcium currents (N-, P/Q-, L-, and T-type) [13]; but relies on
extracellular calcium influx [8]; suggesting a member of the TRP
channel family [13]. Our previous work in the rat found that the
inorganic dye ruthenium red (RuR), a broad spectrum TPRV ion
channel pore blocker, largely attenuated CCK-induced increases
in calcium [13]. Presently, we report that CCK-induced increases
in cytosolic calcium are equally sensitive to RuR in both mouse
species relative to the rat. This finding suggests the CCK-targeted
conductance(s) may be the same across species. Considering CCK
activates vagal afferents in the presence of the TRPV1 antagonist
SB366791 and in CAP insensitive afferents, alternative TRPV
channels (TRPV2–6) are more likely potential mediators. It is
noteworthy that the attenuation of the calcium signal by RuR was
incomplete in all species/strains suggesting that while a RuR-
sensitive conductance has a prominent role in the response to
CCK, there are likely to be additional pathways for calcium entry
that are activated.
Actions of the CCK Analogue JMV-180
The CCK receptor couples to multiple signaling pathways
through distinct affinity states on the CCK-1 receptor [15,43].
Analogues of the CCK molecule have been developed previously
and enabled pharmacological dissection of CCK/CCK-1 receptor
binding, activation and signal transductions pathways in pancre-
atic acinar cells [44–46]. The truncated CCK-8 analogue, JMV-
180, is proposed to have differential effects at the high and low
affinity binding sites on CCK-1 receptors. In both rat and mouse
acini it is an agonist at the high affinity site which mediates
amylase secretion, but an antagonist at the low affinity site only in
the rat [47]. The high affinity site is thought to stimulate acini cells
through PLA2 [48,49] independently of the PLC/diacylglycerol
(DAG)/inositol trisphosphate (IP3) pathway [33,50,51]. In con-
trast, the low affinity site couples to activation of the PLC/DAG/
IP3 pathway [28,33]; where low levels of activation augment
Figure 4. CCK activation of primary vagal afferents is dependent on a Ruthenium Red sensitive conductance. A, upper: representative
trace showing attenuation of CCK (10 nM) induced increase in cytosolic calcium following pretreatment with RuR (10 mM) in a nodose neuron from a
C57BL/6 mouse. Bottom: control response to three consecutive challenges showing neither attenuation nor desensitization of the CCK induced
response with repeated challenges. B, upper: Across neurons, RuR (10 mM) attenuated the average CCK activated calcium transient, while the
control (bottom) was unaltered. Traces are the average 6 SEM of responsive neurons (RuR, n = 6, black line; control n = 6, colored line) C) RuR
significantly reduced CCK induced calcium influx in the SD rat (left; control (red line and points), n = 4; RuR 10 mM (grey), *p , 0.05, n = 8; and RuR
30 mM (black), **p , 0.01, n = 6), in the BalbC mouse (middle; control (green line and points), n = 5; RuR 10 mM (grey), **p , 0.01, n = 9; and RuR
30 mM (black), *p , 0.05, n = 5), and in the C57BL/6 mouse (right; control (blue line and points), n = 6; RuR 10 mM (grey), *p , 0.05, n = 6; and RuR
30 mM (black), **p , 0.01, n = 9). Values are normalized to the first CCK challenge (CCK1) and are expressed as average 6 SEM.
doi:10.1371/journal.pone.0034755.g004
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secretion [33]. This dichotomy in signaling likely underlies the
differential effects of JMV-180 between the rat and mouse species.
JMV-180 is a partial agonist at this low affinity site with different
degrees of efficacy in the mouse versus the rat [20,29,31–33]. For
example, in the mouse JMV-180 is 45% as effective as CCK in
stimulating phosphoinositol (PI) breakdown, whereas in the rat it is
only 20% as effective [29]. Because JMV-180 does not cause
inhibition of amylase secretion in the rat but does in the mouse
[20,33,47] it has been discussed as being an agonist at this site in
the mouse but an antagonist in the rat; whereas at events more
proximal to the activated receptor, such as phosphoinositides
breakdown (Bianchi et al., 1994), the partial agonist behavior of
the analogue is more apparent.
Since the low affinity site mediates CCK-induced vagal afferent
activation [8,16], we expected JMV-180 would block CCK action
in rat and mimic them in the mouse strains. However, we found it
produced no effect by itself and completely blocked CCK actions
in both species. The low affinity site on the CCK-1 receptor
couples through a Gq mediated pathway to activate PLC and
subsequent generation of DAG and IP3 [28,33]. Further, since
CCK-responses are sensitive to RuR and inhibited by the PLC
inhibitor, U73122, but not sensitive to PKC inhibitors, we
previously concluded that PLC induced changes in the membrane
phospholipid content leads to increased activation of a RuR-
sensitive TRP channel [18,52]. Our current results suggest that
either CCK operates via another yet identified pathway from the
PLC/DAG/IP3 activation pathway to activate vagal afferents; or
that the limited efficacy of JMV-180 to activate this pathway [29]
is inadequate to induce activation of RuR-sensitive TRP channels.
Thus although JMV-180 is frequently referred to as an agonist at
the low affinity site in the mouse, because it is only a partial agonist
at this site with limited efficacy, in the case of activating vagal
afferents from the mouse, it is a functional antagonist.
In regards to satiation, JMV-180 has been reported to block
CCK-inducedsatiationinrat,buttopromotesatiationinthemouse,
Figure 5. CCK activation of primary vagal afferents is blocked by CCK analog JMV-180 (JMV) across species. A) Representative traces
showing effect of JMV-180 (100 nM) on the calcium response induced by CCK (10 nM) in SD rat (top), BalbC mouse (middle), and C57BL/6 mouse
(bottom). B) Average calcium levels in response to challenge with CCK alone (colored, first challenge) and challenge to CCK in presence of JMV-180
(grey). Traces are the average 6 SEM of responsive neurons (SD rat,n=4 ;BalbC mouse,n=5 ;C57BL/6 mouse, n = 6). C) JMV significantly decreased
CCK-induced calcium influx in a reversible manner. Colored points and lines are from three challenges to CCK without JMV present in the middle
challenge. Black points and lines are when JMV-180 was present during the second challenge with CCK (CCK2). Results have been normalized to the
first CCK challenge (CCK1) and are the average 6 SEM. (SD rat,p, 0.05, n = 4; BalbC,p, 0.05, n = 5; C57BL/6,p, 0.01, n = 6; *p, 0.05 and
**p,0.01 by paired t-test).
doi:10.1371/journal.pone.0034755.g005
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demonstrate JMV-180 has only antagonistic actions on isolated
mouse nodose neurons, and suggest the satiating effect of JMV-180
inmiceisnotmediatedbyvagalafferentactivation.Itispossiblethat
thisdiscrepancymaybeduetostraindifferencesinmicetestedsince
the previous in vivo work used outbred ICR mice (Harlan Sprague
Dawley) [17]. In acini the partial agonist behavior of JMV-180 is
influenced by both primary structure and the cellular context in
which the receptor is expressed [53–55]. Thus it is possible that
JMV-180 works differently in outbred ICR mice than in Balb/C or
C57BL/6 mouse models. Alternatively, the very high doses of JMV-
180 administered to observe satiation may have been sufficient to
activate CCK receptors at multiple sites, producing a net satiating
effect. Resolution of this discrepancy may prove difficult in vivo
considering the distribution of CCK-1 receptors in tissues
controlling digestion and food intake [56].
Conclusions
The findings in the current study indicate the general
phenotype of CCK activation of vagal afferent neurons is
conserved between rat and mouse species. As such, genetic
knockouts, and other experimental manipulations in the mouse,
may allow for the identification of the cellular transduction
pathway and membrane conductance(s) targeted by CCK.
Further, detailed mechanisms of CCK activity delineated in
the mouse are likely to generalize to the rat. Of specific note is
that resolving the basis for the lack of action of JMV-180 in
isolated nodose neurons from mouse relative to its known
actions in acinar cells may prove insightful into the final
delineation of the transduction pathway activated by CCK in
nodose neurons. Continued progress utilizing these animal
models should clarify CCK induced actions at vagal afferent
neurons and its role in feeding and neuroimmune responses.
Author Contributions
Conceived and designed the experiments: DCK JHP SMS. Performed the
experiments: DCK JHP. Analyzed the data: DCK JHP SMS. Contributed
reagents/materials/analysis tools: SMS. Wrote the paper: DCK JHP SMS.
References
1. Ritter RC (2004) Gastrointestinal mechanisms of satiation for food. Physiol
Behav 81: 249–273.
2. Berthoud HR, Neuhuber WL (2000) Functional and chemical anatomy of the
afferent vagal system. Auton Neurosci 85: 1–17.
3. Dockray GJ (2009) Cholecystokinin and gut-brain signalling. Regul Pept 155: 6–
10. S0167–0115(09)00075–5 [pii];10.1016/j.regpep.2009.03.015 [doi].
4. Grundy D (2006) Signalling the state of the digestive tract. Auton Neurosci 125:
76–80. S1566–0702(06)00012–9 [pii];10.1016/j.autneu.2006.01.009 [doi].
5. Peters JH, Ritter RC, Simasko SM (2006) Leptin and CCK selectively activate
vagal afferent neurons innervating the stomach and duodenum. Am J Physiol
Regul Integr Comp Physiol 290: R1544-R1549. 00811.2005 [pii];10.1152/
ajpregu.00811.2005 [doi].
6. Dun NJ, Wu SY, Lin CW (1991) Excitatory effects of cholecystokinin
octapeptide on rat nodose ganglion cells in vitro. Brain Res 556: 161–164.
7. Lankisch TO, Tsunoda Y, Lu Y, Owyang C (2002) Characterization of CCK(A)
receptor affinity states and Ca(2+) signal transduction in vagal nodose ganglia.
Am J Physiol Gastrointest Liver Physiol 282: G1002-G1008. 10.1152/
ajpgi.00313.2001 [doi].
8. Simasko SM, Wiens J, Karpiel A, Covasa M, Ritter RC (2002) Cholecystokinin
increases cytosolic calcium in a subpopulation of cultured vagal afferent neurons.
Am J Physiol Regul Integr Comp Physiol 283: R1303-R1313. 10.1152/
ajpregu.00050.2002 [doi];00050.2002 [pii].
9. Widdop RE, Krstew E, Mercer LD, Carlberg M, Beart PM, et al. (1994)
Electrophysiological and autoradiographical evidence for cholecystokinin A
receptors on rat isolated nodose ganglia. J Auton Nerv Syst 46: 65–73.
10. Heldsinger A, Grabauskas G, Song I, Owyang C (2011) Synergistic interaction
between leptin and cholecystokinin in the rat nodose ganglia is mediated by
PI3K and STAT3 signaling pathways: implications for leptin as a regulator of
short term satiety. J Biol Chem 286: 11707–11715. M110.198945 [pii];10.1074/
jbc.M110.198945 [doi].
11. Peters JH, Ritter RC, Simasko SM (2005) Leptin and CCK modulate
complementary background conductances to depolarize cultured nodose
neurons. Am J Physiol Cell Physiol.
12. Simasko SM, Ritter RC (2003) Cholecystokinin Activates Both A-Type and C-
Type Vagal Afferent Neurons. Am J Physiol Gastrointest Liver Physiol.
13. Zhao H, Simasko SM (2010) Role of transient receptor potential channels in
cholecystokinin-induced activation of cultured vagal afferent neurons. Endocri-
nology 151: 5237–5246. en.2010–0504 [pii];10.1210/en.2010–0504 [doi].
14. Cawston EE, Miller LJ (2010) Therapeutic potential for novel drugs targeting
the type 1 cholecystokinin receptor. Br J Pharmacol 159: 1009–1021. BPH489
[pii];10.1111/j.1476–5381.2009.00489.x [doi].
15. Williams JA, Sans MD, Tashiro M, Schafer C, Bragado MJ, et al. (2002)
Cholecystokinin activates a variety of intracellular signal transduction mecha-
nisms in rodent pancreatic acinar cells. Pharmacol Toxicol 91: 297–303.
16. Li Y, Wu X, Zhou S, Owyang C (2011) Low-affinity CCK-A receptors are
coexpressed with leptin receptors in rat nodose ganglia: implications for leptin as
a regulator of short-term satiety. Am J Physiol Gastrointest Liver Physiol 300:
G217-G227. ajpgi.00356.2010 [pii];10.1152/ajpgi.00356.2010 [doi].
17. Weatherford SC, Laughton WB, Salabarria J, Danho W, Tilley JW, et al. (1993)
CCK satiety is differentially mediated by high- and low-affinity CCK receptors
in mice and rats. Am J Physiol 264: R244–R249.
18. Zhao H, Sprunger LK, Simasko SM (2010) Expression of transient receptor
potential channels and two-pore potassium channels in subtypes of vagal afferent
neurons in rat. Am J Physiol Gastrointest Liver Physiol 298: G212-G221.
ajpgi.00396.2009 [pii];10.1152/ajpgi.00396.2009 [doi].
19. Zhang L, Jones S, Brody K, Costa M, Brookes SJ (2004) Thermosensitive
transient receptor potential channels in vagal afferent neurons of the mouse. Am
J Physiol Gastrointest Liver Physiol 286: G983-G991. 10.1152/
ajpgi.00441.2003 [doi];00441.2003 [pii].
20. Matozaki T, Martinez J, Williams JA (1989) A new CCK analogue differentiates
two functionally distinct CCK receptors in rat and mouse pancreatic acini.
Am J Physiol 257: G594–G600.
21. Crawley JN, Belknap JK, Collins A, Crabbe JC, Frankel W, et al. (1997)
Behavioral phenotypes of inbred mouse strains: implications and recommenda-
tions for molecular studies. Psychopharmacology (Berl) 132: 107–124.
22. de Jonge WJ, van der Zanden EP, The FO, Bijlsma MF, van Westerloo DJ, et al.
(2005) Stimulation of the vagus nerve attenuates macrophage activation by
activating the Jak2-STAT3 signaling pathway. Nat Immunol 6: 844–851.
23. Gaisano GG, Park SJ, Daly DM, Beyak MJ (2010) Glucagon-like peptide-1
inhibits voltage-gated potassium currents in mouse nodose ganglion neurons.
Neurogastroenterol Motil 22: 470–9, e111. NMO1430 [pii];10.1111/j.1365–
2982.2009.01430.x [doi].
24. Duclaux R, Mei N, Ranieri F (1976) Conduction velocity along the afferent
vagal dendrites: a new type of fibre. J Physiol 260: 487–495.
25. Holzer P (1991) Capsaicin: Cellular targets, mechanisms of action, and
selectivity for thin sensory neurons. Pharmacol Rev 43: 143–201.
26. Chung E, Gu Q, Kwong K, Arden WA, Lee LY (2002) Comparison of
capsaicin-evoked calcium transients between rat nodose and jugular ganglion
neurons. Auton Neurosci 97: 83–88. S1566–0702(02)00045–0 [pii].
27. Wank SA (1995) Cholecystokinin receptors. Am J Physiol 269: G628–G646.
28. Yule DI, Tseng MJ, Williams JA, Logdson CD (1993) A cloned CCK-A receptor
transduces multiple signals in response to full and partial agonists. Am J Physiol
265: G999–1004.
29. Bianchi BR, Miller TR, Witte DG, Lin CW (1994) Novel CCK analogues and
bombesin: a detailed analysis between phosphoinositide breakdown and high-
dose inhibition of pancreatic enzyme secretion in three rodent species.
J Pharmacol Exp Ther 268: 996–1002.
30. Schwartz GJ, McHugh PR, Moran TH (1994) Pharmacological dissociation of
responses to CCK and gastric loads in rat mechanosensitive vagal afferents.
Am J Physiol 267: R303–R308.
31. Archer-Lahlou E, Escrieut C, Clerc P, Martinez J, Moroder L, et al. (2005)
Molecular mechanism underlying partial and full agonism mediated by the
human cholecystokinin-1 receptor. J Biol Chem 280: 10664–10674.
M409451200 [pii];10.1074/jbc.M409451200 [doi].
32. Sarri E, Ramos B, Salido GM, Claro E (2001) The cholecystokinin analogues
JMV-180 and CCK-8 stimulate phospholipase C through the same binding site
of CCK(A) receptor in rat pancreatic acini. Br J Pharmacol 133: 1227–1234.
10.1038/sj.bjp.0704190 [doi].
33. Sato S, Stark HA, Martinez J, Beaven MA, Jensen RT, et al. (1989) Receptor
occupation, calcium mobilization, and amylase release in pancreatic acini: effect
of CCK-JMV-180. Am J Physiol 257: G202–G209.
34. Ritter RC, Ladenheim EE (1985) Capsaicin pretreatment attenuates suppression
of food intake by cholecystokinin. Am J Physiol 248: R501–R504.
35. Ralevic V, Jerman JC, Brough SJ, Davis JB, Egerton J, et al. (2003)
Pharmacology of vanilloids at recombinant and endogenous rat vanilloid
receptors. Biochem Pharmacol 65: 143–151. S000629520201451X [pii].
Conserved CCK Activation of Vagal Afferents
PLoS ONE | www.plosone.org 8 April 2012 | Volume 7 | Issue 4 | e3475536. Smart D, Jerman JC, Gunthorpe MJ, Brough SJ, Ranson J, et al. (2001)
Characterisation using FLIPR of human vanilloid VR1 receptor pharmacology.
Eur J Pharmacol 417: 51–58. S0014–2999(01)00901–3 [pii].
37. Correll CC, Phelps PT, Anthes JC, Umland S, Greenfeder S (2004) Cloning and
pharmacological characterization of mouse TRPV1. Neurosci Lett 370: 55–60.
S0304–3940(04)00941–3 [pii];10.1016/j.neulet.2004.07.058 [doi].
38. Peters JH, McDougall SJ, Fawley JA, Smith SM, Andresen MC (2010) Primary
afferent activation of thermosensitive TRPV1 triggers asynchronous glutamate
release at central neurons. Neuron 65: 657–669. S0896–6273(10)00108-X
[pii];10.1016/j.neuron.2010.02.017 [doi].
39. Shoudai K, Peters JH, McDougall SJ, Fawley JA, Andresen MC (2010)
Thermally active TRPV1 tonically drives central spontaneous glutamate release.
J Neurosci 30: 14470–14475. 30/43/14470 [pii];10.1523/JNEUROSCI.2557–
10.2010 [doi].
40. Peters JH, Karpiel AB, Ritter RC, Simasko SM (2004) Cooperative activation of
cultured vagal afferent neurons by leptin and cholecystokinin. Endocrinology
145: 3652–3657. 10.1210/en.2004–0221 [doi];en.2004–0221 [pii].
41. Powley TL, Phillips RJ (2002) Musings on the wanderer: what’s new in our
understanding of vago-vagal reflexes? I. Morphology and topography of vagal
afferents innervating the GI tract. Am J Physiol Gastrointest Liver Physiol 283:
G1217–G1225. 10.1152/ajpgi.00249.2002 [doi];00249.2002 [pii].
42. Weatherford SC, Chiruzzo FY, Laughton WB (1992) Satiety induced by
endogenous and exogenous cholecystokinin is mediated by CCK-A receptors in
mice. Am J Physiol 262: R574–R578.
43. Wank SA (1998) G protein-coupled receptors in gastrointestinal physiology I.
CCK receptors: an exemplary family. Am J Physiol 274: G607–G613.
44. Fulcrand P, Rodriguez M, Galas MC, Lignon MF, Laur J, et al. (1988) 2-
Phenylethyl ester and 2-phenylethyl amide derivative analogues of the C-
terminal hepta- and octapeptide of cholecystokinin. Int J Pept Protein Res 32:
384–395.
45. Galas MC, Lignon MF, Rodriguez M, Mendre C, Fulcrand P, et al. (1988)
Structure-activity relationship studies on cholecystokinin: analogues with partial
agonist activity. Am J Physiol 254: G176–G182.
46. Rodriguez M, Lignon MF, Galas MC, Fulcrand P, Mendre C, et al. (1987)
Synthesis and biological activities of pseudopeptide analogues of the C-terminal
heptapeptide of cholecystokinin. On the importance of the peptide bonds. J Med
Chem 30: 1366–1373.
47. Stark HA, Sharp CM, Sutliff VE, Martinez J, Jensen RT, et al. (1989) CCK-
JMV-180: a peptide that distinguishes high-affinity cholecystokinin receptors
from low-affinity cholecystokinin receptors. Biochim Biophys Acta 1010: 145–
150. 0167–4889(89)90154–7 [pii].
48. Lankisch TO, Nozu F, Owyang C, Tsunoda Y (1999) High-affinity
cholecystokinin type A receptor/cytosolic phospholipase A2 pathways mediate
Ca2+ oscillations via a positive feedback regulation by calmodulin kinase in
pancreatic acini. Eur J Cell Biol 78: 632–641.
49. Tsunoda Y, Owyang C (1995) High-affinity CCK receptors are coupled to
phospholipase A2 pathways to mediate pancreatic amylase secretion.
Am J Physiol 269: G435–G444.
50. Saluja AK, Dawra RK, Lerch MM, Steer ML (1992) CCK-JMV-180, an analog
of cholecystokinin, releases intracellular calcium from an inositol trisphosphate-
independent pool in rat pancreatic acini. J Biol Chem 267: 11202–11207.
51. Yule DI, Williams JA (1992) U73122 inhibits Ca2+ oscillations in response to
cholecystokinin and carbachol but not to JMV-180 in rat pancreatic acinar cells.
J Biol Chem 267: 13830–13835.
52. Zhao H, Kinch DC, Simasko SM (2011) Pharmacological investigations of the
cellular transduction pathways used by cholecystokinin to activate nodose
neurons. Auton Neurosci. S1566–0702(11)00099–3 [pii];10.1016/j.aut-
neu.2011.05.004 [doi].
53. Ghanekar D, Hadac EM, Holicky EL, Miller LJ (1997) Differences in partial
agonist action at cholecystokinin receptors of mouse and rat are dependent on
parameters extrinsic to receptor structure: molecular cloning, expression and
functional characterization of the mouse type A cholecystokinin receptor.
J Pharmacol Exp Ther 282: 1206–1212.
54. Ji B, Kopin AS, Logsdon CD (2000) Species differences between rat and mouse
CCKA receptors determine the divergent acinar cell response to the
cholecystokinin analog JMV-180. J Biol Chem 275: 19115–19120. 10.1074/
jbc.M001685200 [doi];M001685200 [pii].
55. Poosti R, di ML, Gagne D, Bernad N, Galleyrand JC, Escrieut C, et al. (2000)
The third intracellular loop of the rat and mouse cholecystokinin-A receptors is
responsible for different patterns of gene activation. Mol Pharmacol 58:
1381–1388.
56. Crawley JN, Corwin RL (1994) Biological actions of cholecystokinin. Peptides
15: 731–755. 0196–9781(94)90104-X [pii].
Conserved CCK Activation of Vagal Afferents
PLoS ONE | www.plosone.org 9 April 2012 | Volume 7 | Issue 4 | e34755